$0.27
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. The company is headquartered in Thessaloniki, Central Macedonia and currently employs 163 full-time employees. The company went IPO on 2010-05-19. The firm owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. The company also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Country

GR

CEO

Mr. Grigorios Siokas

IPO date

2010

Employees

163

ISIN

US2214133058

Key stats

Open

$0.27

Volume

8.54M

Market cap

$26.80M

Prev. close

$0.26

Impl / hst vl

-

Open interest

$0.00

$0.25

Day’s Range

$0.27

$0.16

52W Range

$0.57

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
0.36
P/B
1.30
Current ratio
1.05
Debt / Equity
0.74
ROE
-118.89%
Gross margin
7.96%
Income growth
116.96%
FCF growth
66.98

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$4.59
The top 3 analysts forecasts that 12-month price may increase by 1,600.00%, with a low of $4.55 and a high of $4.73
$4.55
Low
$4.59
Avg
$4.73
High
Current price

Earnings

Q2 ‘26 revenue
$18.99M
Q2 ‘26 net income
-$6.09M
Revenue
Net income
Previous EPS
-$0.06
Estimate EPS
$0.01
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply